Abstract
Synovial sarcoma is an aggressive soft tissue sarcoma with only a modest response to conventional cytotoxic agents. In the present study, we evaluated the potential antitumor effects of a novel anti-angiogenesis agent, pazopanib, against synovial sarcoma cells. We found that pazopanib directly inhibited the growth of synovial sarcoma cells by inducing G1 arrest. Multiplex analyses revealed that the PI3K-AKT pathway was highly suppressed in pazopanib-sensitive synovial sarcoma cells. Furthermore, administration of pazopanib highly suppressed the tumor growth in a xenograft model. Taken together, these results suggest pazopanib as a possible agent against synovial sarcoma and may warrant further clinical studies.
Original language | English |
---|---|
Pages (from-to) | 1493-1498 |
Number of pages | 6 |
Journal | Journal of Orthopaedic Research |
Volume | 30 |
Issue number | 9 |
DOIs | |
Publication status | Published - 2012 Sep |
Keywords
- PI3K-AKT pathway
- molecular targeted therapy
- pazopanib
- synovial sarcoma
ASJC Scopus subject areas
- Orthopedics and Sports Medicine